Lipoprotein(a) Test Explained: High Lp(a) Risk for Heart Attack, Normal Range & What to Do (India 2026) | Lp(a) टेस्ट गाइड
Lipoprotein(a) Test Explained: Normal Range, High Levels & Heart Attack Risk (India 2026)
Lp(a) लिपोप्रोटीन टेस्ट: नॉर्मल रेंज, हाई लेवल का मतलब और हार्ट अटैक का जोखिम — पूरी गाइड
You just received your lipid profile report and spotted "Lipoprotein(a)" or "Lp(a)" — a test that many patients have never heard of but that their cardiologist has specifically requested. Lp(a) is often called the "hidden" or "forgotten" cardiovascular risk factor because it is genetically determined, not affected by diet or exercise, and routinely missed in the standard cholesterol (lipid profile) test. Yet elevated Lp(a) is now recognised by the European Atherosclerosis Society, American Heart Association, and Indian cardiac guidelines as an independent, causal risk factor for heart attack, stroke, and aortic valve disease — regardless of LDL cholesterol levels.
This guide explains Lp(a) in simple English and Hindi — what it is, normal ranges used in Indian labs, what high levels mean, which Indians are at highest risk, and what can be done about it. Lp(a) is ordered as part of a comprehensive cardiac risk assessment alongside the standard lipid profile. For reading lab reports generally, see our beginner's guide to blood test reports.
Lp(a) — लिपोप्रोटीन(a) — को "छिपा हुआ" हृदय जोखिम कारक कहा जाता है। यह आनुवंशिक रूप से निर्धारित होता है, आहार या व्यायाम से प्रभावित नहीं होता, और मानक कोलेस्ट्रॉल परीक्षण में शामिल नहीं होता। उच्च Lp(a) हृदयाघात, स्ट्रोक और महाधमनी वाल्व रोग का स्वतंत्र कारण है। Table of Contents / विषय सूची
What Is Lipoprotein(a)? / लिपोप्रोटीन(a) क्या है?
Lipoprotein(a) — written as Lp(a) and pronounced "L-P-little-a" — is a lipoprotein particle structurally similar to LDL (Low-Density Lipoprotein, the "bad cholesterol"), but with an additional large glycoprotein called apolipoprotein(a) [apo(a)] covalently attached to the apolipoprotein B-100 (apoB) protein. This extra apo(a) component is what makes Lp(a) uniquely dangerous compared to regular LDL. Lp(a) was first described by Norwegian geneticist Kåre Berg in 1963 and has been studied for over 60 years — but only in the last decade has it been recognised as a major independent, causal cardiovascular risk factor worthy of routine clinical testing.
Lp(a) एक लिपोप्रोटीन कण है जो LDL ("खराब कोलेस्ट्रॉल") के समान है लेकिन इसमें एक अतिरिक्त glycoprotein — apolipoprotein(a) — जुड़ा होता है। यह अतिरिक्त प्रोटीन Lp(a) को LDL से अधिक खतरनाक बनाता है।- Atherogenic: Like LDL, Lp(a) deposits in arterial walls and promotes atherosclerotic plaque formation — but more efficiently because the apo(a) component makes it stickier to damaged arterial surfaces.
- Prothrombotic (pro-clotting): The apo(a) protein has structural similarity to plasminogen — a clot-dissolving protein. Lp(a) competes with plasminogen for binding sites, impairing the body's natural clot-dissolving (fibrinolytic) system — increasing the risk of acute clot formation on vulnerable plaques (triggering heart attacks).
- Pro-inflammatory: Oxidised phospholipids (OxPL) carried on Lp(a) promote vascular inflammation, contribute to calcification of the aortic valve, and accelerate plaque vulnerability.
Normal Range in India / भारत में सामान्य सीमा
*Important: Lp(a) is reported in two different units — mg/dL or nmol/L. These are NOT directly interchangeable. Always check which unit your lab uses and compare with the reference range on your specific report. The 50 mg/dL threshold ≈ 125 nmol/L but this conversion is approximate and isoform-dependent.
*Lp(a) दो इकाइयों में रिपोर्ट किया जाता है — mg/dL या nmol/L। ये सीधे बदले नहीं जा सकते। अपनी लैब रिपोर्ट की इकाई जांचें।| Lp(a) Level | mg/dL | nmol/L | Risk Category / जोखिम | Clinical Action |
|---|---|---|---|---|
| Desirable | < 30 mg/dL | < 75 nmol/L | Low cardiovascular risk from Lp(a) | No Lp(a)-specific intervention. Standard cardiovascular risk prevention. |
| Borderline | 30–50 mg/dL | 75–125 nmol/L | Intermediate — monitor other risk factors closely | Intensify LDL lowering if other risk factors present. Lifestyle optimisation. Family screening. |
| High | > 50 mg/dL | > 125 nmol/L | Elevated cardiovascular risk — EAS 2022 threshold for intervention | Aggressive LDL-C lowering to below 70 mg/dL (or <55 mg/dL if prior event). Consider statin intensification. Screen all first-degree relatives. |
| Very High | > 90 mg/dL | > 200 nmol/L | Very high risk — equivalent to familial hypercholesterolaemia in risk magnitude | Maximum intensity LDL lowering. PCSK9 inhibitors (evolocumab, alirocumab) modestly reduce Lp(a) by 20–30%. Emerging: RNA-targeted therapy (pelacarsen). Specialist cardiology referral. |
Why High Lp(a) Is Dangerous
High Lp(a) is an independent causal risk factor — meaning it causes cardiovascular disease directly, not just as a marker of something else. Mendelian randomisation studies (genetic studies using LPA gene variants as natural experiments) have conclusively established that genetically elevated Lp(a) causes ASCVD, not merely correlates with it. The most important cardiovascular consequences:
उच्च Lp(a) एक स्वतंत्र कारण जोखिम कारक है — यह केवल किसी अन्य चीज़ का मार्कर नहीं है। Mendelian randomisation अध्ययनों ने स्थापित किया है कि आनुवंशिक रूप से ऊंचा Lp(a) ASCVD का कारण बनता है।Large Mendelian randomisation studies show that each doubling of Lp(a) levels increases the risk of coronary artery disease by approximately 22% and heart attack by 20%. Lp(a) above 50 mg/dL is associated with a 1.5–3× increased risk of myocardial infarction. This risk is additive to — not replaced by — LDL cholesterol risk. A person with normal LDL but very high Lp(a) has significantly elevated heart attack risk that standard lipid profile testing completely misses. This is particularly important for young Indians having premature heart attacks with apparently normal cholesterol.
High Lp(a) increases ischaemic stroke risk by 1.4–1.8×, particularly cardioembolic stroke from aortic arch atherosclerosis and large artery atherosclerosis. The prothrombotic properties of Lp(a) (inhibiting fibrinolysis) may contribute to cerebral venous thrombosis as well. Lp(a) testing is especially recommended in young stroke patients (below 55) without conventional risk factors, where inherited Lp(a) elevation is a common overlooked cause.
Lp(a) is a specific risk factor for calcific aortic valve stenosis — the most common valvular heart disease requiring surgery in India (aortic valve replacement). The oxidised phospholipids (OxPL) carried on Lp(a) particles preferentially accumulate in aortic valve leaflets and promote calcium deposition, progressive valvular sclerosis, and ultimately haemodynamically significant stenosis. Multiple studies show that Lp(a) above 30 mg/dL significantly increases the rate of aortic valve calcification progression. No medical treatment currently slows this — but statin-lowering of LDL does not reduce the risk, whereas Lp(a) lowering (emerging therapies) may.
High Lp(a) is associated with premature peripheral arterial disease — atherosclerosis in the arteries of the legs — causing claudication (leg pain on walking), critical limb ischaemia, and amputation risk. PAD in Indian patients is frequently underdiagnosed. Elevated Lp(a) combined with diabetes (very common in India) dramatically accelerates lower limb arterial disease. Patients with unexplained PAD below age 60, especially with normal LDL, should have Lp(a) measured.
Who Should Get Tested? / किसे टेस्ट करवाना चाहिए?
Current international guidelines (EAS 2022, AHA/ACC 2019 risk calculator enhancement) recommend Lp(a) testing at least once in every adult's lifetime for cardiovascular risk stratification. In India, specific high-priority groups include:
वर्तमान दिशानिर्देश हर वयस्क के जीवनकाल में कम से कम एक बार Lp(a) परीक्षण की सिफारिश करते हैं। भारत में विशेष उच्च-प्राथमिकता समूह:Any person who had a heart attack, stroke, or needed angioplasty/bypass before age 55 (men) or 65 (women) — or has a first-degree relative (parent, sibling) who did. Premature CVD despite normal or well-controlled LDL cholesterol strongly suggests an additional genetic risk factor like elevated Lp(a) or familial hypercholesterolaemia. Lp(a) testing should be part of every premature CVD workup in India.
Lp(a) levels are 90% genetically determined — if a parent or sibling has elevated Lp(a) or premature CVD, each first-degree relative has a 50% chance of similar elevation. All children of a person with very high Lp(a) should be tested. Unlike LDL, Lp(a) levels are established in early childhood and remain stable throughout life — a single test in adulthood is usually sufficient for lifetime risk stratification (Lp(a) does not require periodic repeat testing unless on specific therapy).
A patient who has had a heart attack, received statin therapy, achieved good LDL control (below 70 mg/dL), yet suffered another cardiac event — this "residual cardiovascular risk" despite statin therapy is a classic presentation of elevated Lp(a). Statin therapy reduces LDL by 30–50% but paradoxically increases Lp(a) levels by 10–25% — making Lp(a) measurement before and after statin initiation clinically valuable. If Lp(a) is very high, more aggressive residual risk reduction strategies (PCSK9 inhibitors) are needed.
Indians have a significantly higher prevalence of elevated Lp(a) compared to European populations and develop cardiovascular disease a decade earlier. Indian patients with multiple risk factors (diabetes, hypertension, smoking, central obesity) who fall in the "intermediate risk" category on standard risk calculators — where Lp(a) measurement most changes risk classification — benefit most from testing. Consider testing: any Indian adult with a 10-year ASCVD risk of 5–20% where the result would change treatment intensity decisions.
Any patient with aortic valve calcification or stenosis detected on echocardiography — Lp(a) testing helps explain why this is occurring and risk-stratifies progression. In patients with borderline aortic stenosis (mild-moderate), very high Lp(a) may influence the frequency of echocardiographic follow-up and the threshold for surgical intervention planning.
Lp(a) carries its own cholesterol load — very high Lp(a) (above 100 mg/dL) can contribute 20–50 mg/dL to the calculated LDL-C in the Friedewald equation. If the "LDL cholesterol" appears very high but direct LDL measurement or non-HDL cholesterol is disproportionately elevated, Lp(a) testing helps determine how much of the apparent hypercholesterolaemia is actually attributable to Lp(a) rather than true LDL — with important implications for treatment decisions.
Lp(a) and Indians — Special Concern
South Asians — including Indians — have a well-documented paradox in cardiovascular disease: they develop heart attacks younger, with lower BMI, and often with less severe conventional risk factors (LDL, blood pressure) than predicted by Western risk models. Elevated Lp(a) is one of the key genetic explanations for this South Asian cardiovascular excess risk.
दक्षिण एशियाई — भारतीयों सहित — हृदय रोग में एक विरोधाभास है: वे कम उम्र में, कम BMI के साथ, और अक्सर कम पारंपरिक जोखिम कारकों के साथ हार्ट अटैक विकसित करते हैं। उच्च Lp(a) इस अतिरिक्त जोखिम का एक प्रमुख आनुवंशिक स्पष्टीकरण है।What Can Be Done About High Lp(a)?
This is the most important point: the vast majority of standard interventions that lower LDL do NOT significantly lower Lp(a). Diet changes (even strict low-fat, Mediterranean, or low-carbohydrate diets) have minimal effect — Lp(a) is determined by genetics, not diet. Exercise does not lower Lp(a). Weight loss does not lower Lp(a). Standard statins (atorvastatin, rosuvastatin) — paradoxically — increase Lp(a) by 10–25%. Ezetimibe has no effect on Lp(a). This means a patient told "your cholesterol is fine, keep up the good work with diet and exercise" may still have dangerously elevated Lp(a) that those interventions cannot touch.
PCSK9 inhibitors (evolocumab, alirocumab — injectable biologic antibodies) reduce Lp(a) by 20–30% in addition to dramatically lowering LDL. These are available in India but expensive (₹8,000–15,000 per injection, fortnightly or monthly). Niacin (nicotinic acid) reduces Lp(a) by 20–30% but is no longer recommended due to lack of cardiovascular outcomes benefit and side effects. Hormone replacement therapy (HRT) in post-menopausal women lowers Lp(a) by 20–25%. Lipoprotein apheresis (a machine that physically removes Lp(a) from blood — available at select AIIMS and tertiary cardiology centres) reduces Lp(a) by up to 70% per session, reserved for very high-risk patients.
The most exciting developments in cardiovascular medicine are Lp(a)-specific RNA-targeting therapies: Pelacarsen (antisense oligonucleotide targeting hepatic LPA mRNA) — Phase 3 Lp(a) HORIZON trial completed; reduces Lp(a) by 80%. Olpasiran and SLN360 (siRNA therapies) — reduce Lp(a) by 90%+; Phase 2 completed with impressive results. Muvalaplin (oral small molecule disrupting apo(a)-apoB binding) — Phase 2 data positive. These therapies are not yet approved in India as of 2026 but are expected within 2–3 years — making Lp(a) measurement and documentation now even more important, as future patients with elevated Lp(a) will have specific, highly effective treatment options.
Since Lp(a)-specific therapies are not yet clinically available in India, the current approach is: lower LDL-C aggressively to compensate for the elevated Lp(a)-attributable risk. EAS 2022 guidelines recommend: if Lp(a) is above 50 mg/dL, target LDL-C below 70 mg/dL (for primary prevention) or below 55 mg/dL (for secondary prevention — after a cardiac event). This means more intensive statin therapy + ezetimibe and possibly PCSK9 inhibitors for the LDL component. Additionally: optimal blood pressure control, diabetes management, no smoking, and aspirin in high-risk patients — all reduce overall ASCVD risk even when Lp(a) cannot be lowered.
✅ Book Lipoprotein(a) Test — Home Collection Available
Lp(a) needs to be measured only once in your lifetime for baseline cardiovascular risk stratification. Always order it alongside a full lipid profile for complete cardiac risk assessment:
Affiliate link: I may earn a small commission at no extra cost to you. Prices as of April 2026. Lp(a) testing is available at most major labs — Dr Lal PathLabs, SRL, Metropolis, Thyrocare — typically ₹500–1,500. Always have Lp(a) results interpreted by a cardiologist alongside your full lipid profile, blood pressure, family history, and diabetes status.
Lp(a) जीवन में एक बार परीक्षण — हृदय जोखिम स्तरीकरण के लिए। पूर्ण लिपिड प्रोफाइल के साथ मंगाएं। परिणाम हृदय रोग विशेषज्ञ से समझें। Cardiac Risk Management Tools
While Lp(a) itself cannot be lowered by lifestyle changes, overall cardiovascular risk management for patients with elevated Lp(a) must include optimal blood pressure monitoring and anti-inflammatory nutritional support. Always consult your cardiologist before starting any supplement — particularly if you are on anticoagulants or cardiac medications.
For patients with elevated Lp(a), optimal blood pressure control is critical — hypertension significantly multiplies Lp(a)-attributable cardiovascular risk. Home blood pressure monitoring is recommended by Indian hypertension guidelines for all patients with cardiovascular risk factors, enabling better day-to-day BP tracking between clinic visits. The Omron HEM-7120 is a validated, clinically accurate upper arm BP monitor widely used by Indian cardiologists and their patients. Always consult your cardiologist for BP management.
View on Amazon IndiaAffiliate link — small commission at no extra cost to you.
While omega-3 fatty acids do not directly lower Lp(a), EPA and DHA have well-documented benefits for overall cardiovascular health — reducing triglycerides by 15–30%, reducing vascular inflammation (lowering hs-CRP), mildly improving HDL function, and having anti-arrhythmic effects at high doses. For patients with elevated Lp(a) who need to reduce their overall cardiovascular risk burden as much as possible, omega-3 supplementation is a reasonable adjunct to statin therapy and lifestyle management. Always consult your cardiologist before starting any supplement — high-dose omega-3 may interact with anticoagulants.
View on Amazon IndiaAffiliate link — small commission at no extra cost to you.
Related Tests / संबंधित जांचें
These tests are commonly ordered alongside Lp(a) in the cardiac risk workup:
हृदय जोखिम मूल्यांकन में Lp(a) के साथ ये जांचें अक्सर करवाई जाती हैं:Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल
The desirable Lp(a) level is below 30 mg/dL (below 75 nmol/L). Above 50 mg/dL (above 125 nmol/L) is considered elevated and associated with significantly increased cardiovascular risk — this is the threshold at which the European Atherosclerosis Society 2022 guidelines recommend intensifying LDL-C lowering. Above 90 mg/dL (above 200 nmol/L) is very high and confers a risk equivalent to familial hypercholesterolaemia. Some labs in India report Lp(a) in nmol/L rather than mg/dL — these units are not directly interchangeable. Approximately 20–25% of the global population has Lp(a) above 50 mg/dL, and the prevalence in Indians may be higher. A single Lp(a) measurement in adulthood is sufficient for baseline risk stratification — repeat testing is not needed unless on specific Lp(a)-lowering therapy.
उत्तर: वांछनीय Lp(a): 30 mg/dL से कम। उच्च जोखिम: 50 mg/dL से अधिक। बहुत उच्च जोखिम: 90 mg/dL से अधिक। जीवन में एक बार परीक्षण पर्याप्त है।Yes — this is precisely the situation that Lp(a) testing is designed to identify, and why Lp(a) is not included in the standard lipid profile. An Lp(a) of 60 mg/dL with normal LDL is a genuinely elevated cardiovascular risk that the standard cholesterol panel completely misses. Lp(a) adds cardiovascular risk independently of LDL — a person with normal LDL (below 100 mg/dL) but Lp(a) above 50 mg/dL has approximately 1.5–2× higher risk of heart attack than someone with both normal LDL and normal Lp(a). The current management approach is: even with normal LDL, your cardiologist will likely recommend a lower LDL target (below 70 mg/dL rather than below 100) to compensate for the Lp(a)-attributable risk. This typically requires statin therapy even with "normal" baseline LDL. All your first-degree relatives should also have their Lp(a) measured once.
उत्तर: हां — यही वह स्थिति है जिसके लिए Lp(a) परीक्षण डिज़ाइन किया गया है। Lp(a) 60 mg/dL + सामान्य LDL = बढ़ा हुआ हृदय जोखिम जो मानक कोलेस्ट्रॉल परीक्षण में नहीं दिखता। हृदय रोग विशेषज्ञ अधिक आक्रामक LDL लक्ष्य (<70 mg/dL) सुझाएंगे।Unfortunately, no — this is one of the most frustrating aspects of elevated Lp(a) for patients and doctors alike. Approximately 90% of Lp(a) levels are genetically determined by variations in the LPA gene — primarily the number of kringle-IV type 2 (KIV-2) repeats in the apo(a) protein. No dietary change — including low-fat, low-carbohydrate, Mediterranean, or vegan diet — meaningfully lowers Lp(a). Exercise does not lower Lp(a). Weight loss does not lower Lp(a). In fact, statins — the most commonly prescribed cholesterol-lowering drugs — paradoxically increase Lp(a) by 10–25% (by upregulating LPA gene expression through LDL receptor pathway feedback). This means your Lp(a) will remain elevated regardless of how well you manage your diet and exercise. The response is not nihilism — it means the focus should be on aggressively reducing all other modifiable cardiovascular risk factors (LDL, blood pressure, blood sugar, smoking cessation) that you can influence.
उत्तर: नहीं — Lp(a) 90% आनुवंशिक है। आहार, व्यायाम, या वजन घटाने से Lp(a) कम नहीं होता। स्टेटिन Lp(a) को 10–25% बढ़ा सकते हैं। अन्य परिवर्तनीय जोखिम कारकों (LDL, BP, ब्लड शुगर, धूम्रपान) को नियंत्रित करने पर ध्यान केंद्रित करें।No — fasting is not specifically required for the Lp(a) test itself. Lipoprotein(a) levels are not significantly affected by recent food intake, unlike triglycerides. However, Lp(a) is almost always ordered alongside a full lipid profile (total cholesterol, LDL, HDL, triglycerides, VLDL) — and the lipid profile does require fasting (9–12 hours, no food except water) for accurate triglyceride and calculated LDL results. Therefore, in practice: if you are getting Lp(a) as part of a lipid profile, follow the fasting instructions for the lipid profile. If you are getting Lp(a) alone (for example, a follow-up measurement in a patient already on treatment), you can eat normally.
उत्तर: Lp(a) के लिए उपवास आवश्यक नहीं। लेकिन Lp(a) आमतौर पर लिपिड प्रोफाइल के साथ मंगाया जाता है — और लिपिड प्रोफाइल के लिए 9–12 घंटे का उपवास आवश्यक है।Unlike LDL cholesterol which changes with diet, exercise, and medications, Lp(a) levels are genetically determined and remain remarkably stable throughout adult life — typically varying by less than 10–15% between measurements over decades in the absence of specific therapy. Therefore, for most patients, Lp(a) needs to be measured only once in adulthood for baseline cardiovascular risk stratification. Repeat testing is recommended in specific situations: if you start a PCSK9 inhibitor (evolocumab, alirocumab) to confirm the Lp(a)-lowering response; if you are enrolled in a clinical trial of Lp(a)-specific therapy (pelacarsen, olpasiran); if the initial result was borderline (30–50 mg/dL) and there is clinical uncertainty about risk reclassification; or in the context of specific hormonal changes (menopause — HRT can lower Lp(a) by 20–25% in some women). For most Indian patients, measure once — document in your medical records — and act on the result with appropriate risk reduction strategies.
उत्तर: जीवन में एक बार परीक्षण पर्याप्त है। Lp(a) वयस्क जीवन में स्थिर रहता है। दोबारा परीक्षण: PCSK9 inhibitor शुरू करने पर, Lp(a)-विशिष्ट थेरेपी क्लिनिकल ट्रायल में, या रजोनिवृत्ति के बाद HRT पर।Absolutely yes — and this is one of the most compelling clinical indications for Lp(a) family screening. A parent with premature cardiovascular disease (heart attack or stroke before age 55 in a man, before age 65 in a woman) and apparently normal or only mildly elevated LDL cholesterol is a strong signal that a genetic cardiovascular risk factor — most likely elevated Lp(a) or familial hypercholesterolaemia — was the driving cause. Since Lp(a) levels are 90% genetically inherited, each first-degree relative (children, siblings) of your father has a 50% chance of having similarly elevated Lp(a). The practical recommendation: all adult children and siblings of your father should have Lp(a) measured once. If elevated (>50 mg/dL), they should have their LDL-C managed aggressively even if currently "normal" — and implement comprehensive cardiovascular risk factor control. Children who test positive should be identified early so risk-reducing interventions (statin therapy from early adulthood if LDL is elevated, aggressive blood pressure control, no smoking) can be started before atherosclerotic plaque accumulates over decades.
उत्तर: बिल्कुल हां। 45 वर्ष की उम्र में सामान्य कोलेस्ट्रॉल के साथ हार्ट अटैक = उच्च Lp(a) या पारिवारिक हाइपरकोलेस्ट्रोलेमिया का प्रबल संकेत। पिता के सभी वयस्क बच्चों और भाई-बहनों को एक बार Lp(a) परीक्षण करवाना चाहिए।- European Atherosclerosis Society (EAS) 2022: EAS Consensus Statement on Lp(a) — Lipoprotein(a) and Cardiovascular Disease
- American Heart Association: Lipoprotein(a) and Heart Disease — AHA
- MedlinePlus: Lipoprotein(a) Blood Test — Patient Information
⚠️ Medical Disclaimer / चिकित्सा अस्वीकरण
This article is for educational purposes only. Lp(a) results must always be interpreted by a qualified cardiologist or physician in the context of your full cardiovascular risk profile — age, family history, blood pressure, diabetes, smoking status, LDL cholesterol, and clinical symptoms. Never start or stop medications based on this guide alone. Do not attempt to "treat" high Lp(a) with unproven supplements without specialist guidance.
यह लेख केवल शैक्षिक उद्देश्यों के लिए है। Lp(a) परिणाम हमेशा एक योग्य हृदय रोग विशेषज्ञ द्वारा आपकी पूर्ण हृदय जोखिम प्रोफाइल के संदर्भ में व्याख्या किए जाने चाहिए। केवल इस गाइड के आधार पर कोई दवा शुरू या बंद न करें।
Comments
Post a Comment